Autopsy report · NCT02231710

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

“due to lack of enrollment and changes to the sponsor development portfolio”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 6 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Bellicum Pharmaceuticals

Sponsor type

Industry

Conditions

Primary Immune Deficiency Disorders; Hemophagocytic Lymphohistiocytosis; Inherited Bone Marrow Failure Syndrome; Hemoglobinopathies; Metabolic Disorders

Interventions

BPX-501 and Rimiducid

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
  “Sponsor decision due to lack of enrollment.” (79% match in meaning)
• A Clinical Investigation Evaluating Peristeen® Performance
  “Lack of enrollment - Sponsor decision” (77% match in meaning)
• Digital Remote Home Monitoring for Heart Failure
  “Due to sponsor request for poor enrollment” (74% match in meaning)
• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
  “Sponsor change” (73% match in meaning)
• A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
  “Sponsor decision:Change the Development plan” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.